| Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL (NCT05360238) | Mustang Bio | 2022-05-24 |
| Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma (NCT05318963) | Institute of Hematology & Blood Diseases Hospital, China | 2022-03-14 |
| Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies (NCT06220097) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2022-02-01 |
| Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product. (NCT05645744) | Mustang Bio | 2021-09-29 |
| Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation (NCT04531046) | The Lymphoma Academic Research Organisation | 2021-03-10 |
| Induced-T Cell Like NK Cells for B Cell Malignancies (NCT04747093) | Nanfang Hospital, Southern Medical University | 2021-01-29 |
| CAR T Cell Therapy Related Cardiovascular Outcomes (NCT05130489) | University College London Hospitals | 2021-01-18 |
| A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma (NCT04304040) | Beijing InnoCare Pharma Tech Co., Ltd. | 2020-07-28 |
| CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL (NCT04303247) | Xinqiao Hospital of Chongqing | 2020-05-01 |
| CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies (NCT04214886) | Loyola University | 2019-12-31 |
| MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) (NCT03853616) | Miltenyi Biomedicine GmbH | 2018-11-26 |
| MB-CART20.1 Lymphoma (NCT03664635) | Miltenyi Biomedicine GmbH | 2018-09-25 |
| Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas (NCT01786018) | Azienda Ospedaliera San Giovanni Battista | 2013-02-01 |
| Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma (NCT01535989) | Cristiana Sessa | 2011-12-01 |